Evidence map›Paper›PMID 19394452›Full record

ReviewRespiratory physiology & neurobiology2009

Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth.

David M Katz, Mathias Dutschmann, Jan-Marino Ramirez, Gérard Hilaire

Registry-linked trialAbstract readReview
In one paragraph

Review in Respiratory physiology & neurobiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02790034 (A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms), which is not on this map. Cited by 99 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02790034 phase2 / phase3terminatednot on this mapstarted 2016, after this paper: background citation

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

TypeinterventionalSponsorNewron Pharmaceuticals SPARan2016 to 2020Enrolled129ConditionsRett SyndromeArmsSarizotan low dose, Sarizotan high dose, Placebo
3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Leptin antagonism improves Rett syndrome phenotype in symptomatic Mecp2-deficient mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Inhibitory Synaptic Influences on Developmental Motor Disorders.International journal of molecular sciences · 2023
    Review
  17. 5-HTInternational journal of molecular sciences · 2022
    Article
  18. Sleep Respiratory Disturbances in Girls with Rett Syndrome.International journal of environmental research and public health · 2022
    Article
  19. Article
  20. Breathing disturbances in Rett syndrome.Handbook of clinical neurology · 2022
    Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

David M KatzDepartment of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA. david.katz@case.edu
Mathias Dutschmann
Jan-Marino Ramirez
Gérard Hilaire
Case Western Reserve University · USCentre National de la Recherche Scientifique · FRUniversity of Leeds · GBUniversity of Washington · US

Funding

Respiratory Circuit Dysfunction in Rett SyndromeR01NS057398 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI KATZ, DAVID M. · 2007 to 2013
$3.1M
NINDS NIH HHS R01 NS057398
6 · The paper itself

Abstract

Disorders of respiratory control are a prominent feature of Rett syndrome (RTT), a severely debilitating condition caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MECP2). RTT patients present with a complex respiratory phenotype that can include periods of hyperventilation, apnea, breath holds terminated by Valsalva maneuvers, forced and deep breathing and apneustic breathing, as well as abnormalities of heart rate control and cardiorespiratory integration. Recent studies of mouse models of RTT have begun to shed light on neurologic deficits that likely contribute to respiratory dysfunction including, in particular, defects in neurochemical signaling resulting from abnormal patterns of neurotransmitter and neuromodulator expression. The authors hypothesize that breathing dysregulation in RTT results from disturbances in mechanisms that modulate the respiratory rhythm, acting either alone or in combination with more subtle disturbances in rhythm and pattern generation. This article reviews the evidence underlying this hypothesis as well as recent efforts to translate our emerging understanding of neurochemical defects in mouse models of RTT into preclinical trials of potential treatments for respiratory dysfunction in this disease.

Indexed as

AnimalsAnimals, NewbornBrain-Derived Neurotrophic FactorDisease Models, AnimalDisease ProgressionHumansMethyl-CpG-Binding Protein 2MiceMice, KnockoutNeurochemistryRespiration DisordersRespiratory SystemRett SyndromeBrain-Derived Neurotrophic FactorMethyl-CpG-Binding Protein 2

Identifiers

PMID19394452
PMCPMC2758855
OpenAlexW2088319884

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.